ArtiaBio is a dynamic company specialized on the development of biopharmaceuticals. Our advanced technology in cell line and process development combined with the utilization of advanced bioprocess technology allow development of highly effective manufacturing processes that can provide the biotechnology-based drugs at an affordable price. We have experience and expertise in a broad range of products, including monoclonal antibodies, blood coagulation factors, therapeutic enzymes, and fusion proteins.
ArtiaBio has several parental cell lines, highly productive expression vectors, and owns proprietary media and feeds that yield very excellent productivities in fed-batch and continuous (perfusion).
ArtiaBio has several parental cell lines, highly productive expression vectors, and owns proprietary media and feeds that yield very excellent productivities in fed-batch and continuous (perfusion).
We are specialized in both fed-batch and continuous perfusion and we have expertise with several cell line platforms (CHO, NS0, Sp2/0).
Recombinant DNA Technology
Genetic engineering of mammalian cells using recombinant DNA technology has delivered a new class of medicines that provided safe and effective treatments in the fields of cancer, immunology, dermatology and has resulted in multi-billion dollar industry. Major pharmaceutical companies like Roche/Genentech, Amgen, Janssen, Merck, Pfizer, Biogen, and many other companies have produced medicines that have helped patients for many years.
How ArtiaBio Technology Platform Makes Biotherapeutics Affordable
Biotherapeutics are very expensive, some costing thousands of dollars for a single dose and some cases hundreds of thousands of dollars a year for treatment. This high cost inhibits their use in many countries, and substantially limits their reach to patients in advanced countries like US, Japan, and Europe.
ArtiaBio technology overcomes these limitations by the following strategies;
- ArtiaBio technology allows development of highly productive cell lines and manufacturing processes with fast timelines
- Applying advanced process technology, the processes developed have a great advantage in reducing the timelines and the cost of manufacturing
- ArtiaBio uses very small footprint and utilizes a chain of world-class laboratories to decrease the cost of product development
ArtiaBio Business Model
The ArtiaBio technology platform is the core of the ArtiaBio business model. This technology along with the extensive expertise of the ArtiaBio leadership allows the development of cell lines, manufacturing processes, and biopharmaceutical products. While ArtiaBio develops its own products, it provides services to help other companies to develop their products as well.
ArtiaBio:
- Develops recombinant cell lines and cGMP-ready manufacturing processes as a CDMO
- Licenses its technology platform to partners (cell line development platform, media and feeds)
- Develops biopharmaceutical products and licenses to partners
- Provides solutions for process development and manufacturing
Biotherapeutics are very expensive, some costing thousands of dollars for a single dose and some cases hundreds of thousands of dollars a year for treatment. This high cost inhibits their use in many countries, and substantially limits their reach to patients in advanced countries like US, Japan, and Europe.
ArtiaBio technology overcomes these limitations by the following strategies;
- ArtiaBio technology allows development of highly productive cell lines and manufacturing processes with fast timelines
- Applying advanced process technology, the processes developed have a great advantage in reducing the timelines and the cost of manufacturing
- ArtiaBio uses very small footprint and utilizes a chain of world-class laboratories to decrease the cost of product development
ArtiaBio Business Model
The ArtiaBio technology platform is the core of the ArtiaBio business model. This technology along with the extensive expertise of the ArtiaBio leadership allows the development of cell lines, manufacturing processes, and biopharmaceutical products. While ArtiaBio develops its own products, it provides services to help other companies to develop their products as well.
ArtiaBio:
- Develops recombinant cell lines and cGMP-ready manufacturing processes as a CDMO
- Licenses its technology platform to partners (cell line development platform, media and feeds)
- Develops biopharmaceutical products and licenses to partners
- Provides solutions for process development and manufacturing